NCT03728361: Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have diagnosis of neuroendocrine tumor/carcinoma
Exclusions: Patients with symptomatic, untreated, unstable central nervous system (CNS) metastases and/or leptomeningeal disease – see trial for details; Patients with prior temozolomide treatments & immunotherapy with checkpoint inhibitor (including antibodies to PD-1, PD-L1, & CTLA-4) therapy

Comments are closed.

Up ↑